In terms of regulation 5(4) of the Control of Concentrations Regulations, 2002 published in Legal Notice 294 of 2002, the Director General of the Office for Competition notifies for general information that a notification of a concentration between Artemis Parent Inc. (Ontario, Canada) and Apotex Pharmaceutical Holdings Inc. (Ontario, Canada) was filed on Friday, 21 October 2022.
The nature of the concentration is an indirect acquisition of sole control of Apotex Pharmaceutical Holdings Inc. by Artemis Parent Inc.
Artemis Parent Inc. is a special purpose vehicle incorporated for the purpose of the proposed transaction. Artemis Parent Inc. is owned and controlled by investment funds managed by affiliates of SK Capital Partners, LP which is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. Apotex Pharmaceutical Holdings Inc. is a global pharmaceutical business that develops, manufactures and distributes generic and associated pharmaceutical products, including prescription and over-the-counter products in finished dosage forms, APIs and biosimilars.
The Director General of the Office for Competition invites interested third parties to submit their written objections on this notified concentration within seven days from publication of this notice at the following address: